Search
Clofibrate
go.drugbank.com/drugs/DB00636ApprovedWithdrawnA fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)
Sofosbuvir
go.drugbank.com/drugs/DB08934ApprovedInvestigationalIts use has also proven successful in the treatment of HCV in patients co-infected with HIV [A19627]. … in combination with other antivirals for all six genotypes of Hepatitis C [L852].
Yellow fever vaccine
go.drugbank.com/drugs/DB10805ApprovedInvestigationalYellow Fever is most commonly found in the southern hemisphere, in tropical regions of Africa and Central/South America [L1653]. … Yellow fever vaccine prevents against Yellow Fever, a viral hemorrhagic disease caused by the transmission of a _flavivirus_ through the bite of an infected mosquito.
Vibegron
go.drugbank.com/drugs/DB14895ApprovedInvestigationalOn December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA. … [L28305] Vibegron was first approved in Japan in September 2018 for the treatment of overactive bladder,[A226050] a condition associated with distressing symptoms of urge urinary incontinence, urgency,
Chromium picolinate
go.drugbank.com/drugs/DB11255ApprovedChromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss.
Categories: Compounds used in a research, industrial, or household settingAsunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawnIt has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. … [A32528] It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.[L1113]
Ranibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigationalIn order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use. … [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO.
Products: LUCENTIS 10 MG/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE, LUCENTIS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 1.65mg/0.165mlHydromorphone
go.drugbank.com/drugs/DB00327ApprovedIllicitInvestigationalStructurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 and 8. … [A176495] The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984.[L5795]
Leflunomide
go.drugbank.com/drugs/DB01097ApprovedInvestigationalLeflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
Synonyms: 4-ISOXAZOLECARBOXAMIDE, 5-METHYL-N-(4-(TRIFLUOROMETHYL)PHENYL)-, 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamideObiltoxaximab
go.drugbank.com/drugs/DB05336ApprovedIt has an approximate molecular weight of 148 kDa. … Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin.